Valrubicin
From Wikipedia, the free encyclopedia
Valrubicin
|
|
Systematic (IUPAC) name | |
[2-oxo-2-[2,5,12-trihydroxy-4- [5-hydroxy-6-methyl-4- (2,2,2-trifluoroacetyl) amino-tetrahydropyran-2-yl] oxy-7-methoxy-6,11-dioxo-1,2,3,4-tetrahydrotetracen- 2-yl]-ethyl] pentanoate | |
Identifiers | |
CAS number | 56124-62-0 |
ATC code | L01DB09 |
PubChem | 41744 |
DrugBank | APRD00662 |
Chemical data | |
Formula | C34H36F3NO13 |
Mol. weight | 723.644 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Protein binding | >99% |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Valrubicin (N-trifluoroacetyladriamycin-14-valerate, ValstarĀ®) is a chemotherapy drug used to treat bladder cancer. Valrubicin is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder.
[edit] Dosage
800 mg weekly for 6 weeks
[edit] Side effects
- Blood in urine
- Incontinence
- painful or difficult urination
- Unusually frequent urination